康复期血浆联合药物治疗重症新型冠状病毒肺炎患者：基于新制定的新型冠状病毒肺炎治疗指南的药物分析与药学监护
Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy.
作者信息
Wang Ying, Zhang Yang, Yu Qian, Zhu Kun
机构信息
Department of Pharmacy, The Third Hospital of Jilin University, Jilin University, Changchun, China.
School of Biology and Food Engineering, Changshu Institute of Technology, Changshu, China.
出版信息
Front Pharmacol. 2020 Jun 24;11:966. doi: 10.3389/fphar.2020.00966. eCollection 2020.
Abstract
Given the extreme importance of the current pandemic caused by COVID-19 and due to the fact that scientists agree that there is no identified treatment, this paper analyzes in detail the treatment of a severe COVID-19 patient with convalescent plasma and drugs based on current guidelines for COVID-19 diagnosis and treatment. This can provide a reference for other medical institutions on rational drug use and pharmaceutical care for severe COVID-19 patients.
摘要
鉴于由新型冠状病毒肺炎（COVID-19）引发的当前大流行的极端重要性，且由于科学家们一致认为尚无已确定的治疗方法，本文依据当前COVID-19诊断和治疗指南，详细分析了一名重症COVID-19患者使用康复期血浆和药物的治疗情况。这可为其他医疗机构对重症COVID-19患者合理用药及药学服务提供参考。
相似文献
1
Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy.康复期血浆联合药物治疗重症新型冠状病毒肺炎患者：基于新制定的新型冠状病毒肺炎治疗指南的药物分析与药学监护
Front Pharmacol. 2020 Jun 24;11:966. doi: 10.3389/fphar.2020.00966. eCollection 2020.
2
Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.低剂量放射疗法与恢复期血浆：一种混合方法如何使新冠肺炎患者的益处最大化。
J Biomed Phys Eng. 2020 Aug 1;10(4):387-394. doi: 10.31661/jbpe.v0i0.2006-1125. eCollection 2020 Aug.
3
Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion.新型冠状病毒肺炎的治疗：恢复期血浆输注的前景
Front Med (Lausanne). 2020 Jul 28;7:435. doi: 10.3389/fmed.2020.00435. eCollection 2020.
4
Convalescent plasma: Would it prove to be magic potion/boon in the current scenario of COVID pandemic?康复血浆：在当前新冠疫情的情况下，它会被证明是神奇药水/福音吗？
Asian J Transfus Sci. 2020 Jan-Jun;14(1):1-3. doi: 10.4103/0973-6247.290652. Epub 2020 Jul 24.
5
Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.恢复期血浆疗法治疗新型冠状病毒肺炎：一些思考：通信
Int J Surg. 2020 Aug;80:26. doi: 10.1016/j.ijsu.2020.06.029. Epub 2020 Jun 22.
6
Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19.新型冠状病毒肺炎康复期血浆治疗建议指南。
Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):212-213. doi: 10.1016/j.htct.2021.03.001. Epub 2021 Mar 20.
7
Convalescent plasma: A possible treatment of COVID-19 in India.康复血浆：印度治疗新冠肺炎的一种可能方法。
Med J Armed Forces India. 2020 Apr;76(2):236-237. doi: 10.1016/j.mjafi.2020.04.006. Epub 2020 Apr 15.
8
Covid-19: Convalescent plasma may cut deaths in patients not on ventilation, study indicates.新冠疫情：研究表明，恢复期血浆可能降低未使用呼吸机患者的死亡率。
BMJ. 2021 Jan 14;372:n130. doi: 10.1136/bmj.n130.
9
Follow-up of convalescent COVID-19 patients by the general practitioner.全科医生对新冠康复患者的随访。
Bull Acad Natl Med. 2020 Dec;204(9):e92. doi: 10.1016/j.banm.2020.07.006. Epub 2020 Jul 12.
10
The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy.治疗性血浆置换对COVID-19治疗的影响。
Turk J Pharm Sci. 2020 Oct;17(5):463-464. doi: 10.4274/tjps.galenos.2020.13845. Epub 2020 Oct 30.
引用本文的文献
1
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
2
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
3
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.恢复期血浆或高免疫球蛋白用于 COVID-19 患者：一项实时系统评价。
Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4.
4
Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.用于治疗新型冠状病毒肺炎的恢复期血浆疗法：当前全球大流行中的观点与应用
Risk Manag Healthc Policy. 2020 Nov 23;13:2707-2728. doi: 10.2147/RMHP.S281388. eCollection 2020.
5
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.SARS-CoV-2 重组刺突蛋白纳米颗粒疫苗的 1/2 期临床试验。
N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.
本文引用的文献
1
Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic.新冠疫情期间某指定医院的药品供应和药学服务管理实践。
Res Social Adm Pharm. 2021 Jan;17(1):1978-1983. doi: 10.1016/j.sapharm.2020.04.001. Epub 2020 Apr 6.
2
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
3
Convalescent plasma as a potential therapy for COVID-19.康复期血浆作为治疗新冠肺炎的一种潜在疗法。
Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.
4
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
5
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
6
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
7
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.临床证据不支持使用皮质类固醇治疗2019新型冠状病毒肺炎肺损伤。
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
8
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
9
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
10
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
Zotero 插件